Growing evidence indicates that the overexpression or activation of PKC-α in transgenic mice decreases Ca 2+ transients as well as cardiac contractility, which leads to cardiac hypertrophy and ultimately heart failure (47–50). The gene discussed is PRKCA; the disease is cardiac hypertrophy.